Biocept Announces Master Services Agreement with Pharma Company to Develop Liquid Biopsy Tests
Following the successful completion of the first phase of the agreement,
"As we accumulate more data demonstrating the validity of our dual CTC and ctDNA Target Selector platforms, more pharmaceutical companies are taking notice," said
"We are executing on a stated objective for 2016 of increasing the utilization of our tests in clinical trials and this agreement is our second with a major pharmaceutical company this year," said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the detection
and treatment of cancer, our impact on diagnostic strategies, the amount of work we will perform and the amount of revenue we will generate under the development project, our ability to increase our share of the pharmaceutical clinical trial market and planned future offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-announces-master-services-agreement-with-pharma-company-to-develop-liquid-biopsy-tests-300272665.html
SOURCE
News Provided by Acquire Media